MiniMed Group Inc. Common Stock vs Personalis Inc. Common Stock — how do they compare? MiniMed Group Inc. Common Stock trades at $16.74 (market cap $4.73B), while Personalis Inc. Common Stock trades at $16.14 (market cap $1.70B). The key difference: MiniMed Group Inc. Common Stock is far larger — about 2.8× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is trading nearer its 52-week high, MiniMed Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MiniMed Group Inc. Common Stock for 6 Days and Personalis Inc. Common Stock for 0 Days on average.
| MMED | PSNL | |
|---|---|---|
Market Cap | $4.73B | $1.70B |
Volume | 67,620,827 | 3,262,398 |
Sector | Health | Health |
52-Week High | $23.84 | $18.38 |
52-Week Low | $10.80 | $5.04 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.53B | $1.52B |
Signals from Pluang's Aura AI — not financial advice
MMED trades at $18.40, down 2.13% today, with technical indicators showing bearish momentum. The company reported revenue growth to $2.72B in 2025 but posted a net loss of -$250M. Recent news highlights Medtronic's exchange offer completion and MiniMed's new product launches. Analyst consensus remains strongly bullish with 100% buy ratings and a $25.73 price target, representing 40% upside potential from current levels.
Despite negative profitability metrics and bearish technical signals, MMED maintains strong analyst support and revenue growth trajectory. Key risks include persistent net losses, high short interest, and execution challenges in the competitive diabetes technology market. The stock offers potential upside if new product cycles drive margin improvement and profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →